{"slideshow_credits": null, "snippet": "The anticlotting drug Pradaxa, on the market only two years, is growing in popularity for its ease of use, but it has been associated with hemorrhaging, and it has no antidote to reverse its blood-thinning effects.", "abstract": "Anticlotting drug Pradaxa is growing in popularity for its ease of use, but has been associated with hemorrhaging and has no antidote to reverse its blood-thinning effects; Pradaxa has been linked to more than 500 bleeding deaths in its two years on the market; drug has become a blockbuster for its maker Boehringer Ingelheim, bringing in more than $1 billion in sales.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/11/03/business/a-rising-anti-stroke-drug-is-tied-to-risk-of-bleeding-deaths.html", "lead_paragraph": "The anticlotting drug Pradaxa, on the market only two years, is growing in popularity for its ease of use, but it has been associated with hemorrhaging, and it has no antidote to reverse its blood-thinning effects.", "headline": {"main": "A Promising Drug With a Flaw", "print_headline": "A Promising Drug With a Flaw"}, "_id": "50942fa295e998af7118af5d", "word_count": "1264", "multimedia": [{"height": 360, "url": "images/2012/11/03/business/03bloodthinner/03bloodthinner-articleLarge.jpg", "legacy": {"xlarge": "images/2012/11/03/business/03bloodthinner/03bloodthinner-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "360"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2012/11/03/business/03bloodthinner/03bloodthinner-thumbStandard.jpg", "legacy": {"thumbnail": "images/2012/11/03/business/03bloodthinner/03bloodthinner-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2012-11-03T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Pradaxa (Drug)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Boehringer Ingelheim GmbH", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Deaths (Fatalities)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Blood", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Stroke", "name": "subject", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}